Transplanting liver patients who respond to atezolizumab-bevacizumab is promising for those with intermediate and advanced hepatocellular carcinoma.

• Recurrence-free survival is 90% and overall survival is 94% at two years post-transplant.
• Acute rejection rates are 25%, but remain manageable; 62.5% had complications within 90 days of transplant.

Surgical teams should consider immunotherapy response when selecting candidates for liver transplantation in advanced HCC.